OBJECTIVES: To describe temporal trends in baseline clinical characteristics, initial treatment regimens and monitoring of patients starting antiretroviral therapy (ART) in resource-limited settings. METHODS: We analysed data from 17 ART programmes in 12 countries in sub-Saharan Africa, South America and Asia. Patients aged 16 years or older with documented date of start of highly active ART (HAART) were included. Data were analysed by calculating medians, interquartile ranges (IQR) and percentages by regions and time periods. Not all centres provided data for 2006 and 2005 and 2006 were therefore combined. RESULTS: A total of 36,715 patients who started ART 1996-2006 were included in the analysis. Patient numbers increased substantially in sub-Saharan Africa and Asia, and the number of initial regimens declined, to four and five, respectively, in 2005-2006. In South America 20 regimes were used in 2005-2006. A combination of 3TC/D4T/NVP was used for 56% of African patients and 42% of Asian patients; AZT/3TC/EFV was used in 33% of patients in South America. The median baseline CD4 count increased in recent years, to 122 cells/microl (IQR 53-194) in 2005-2006 in Africa, 134 cells/microl (IQR 72-191) in Asia, and 197 cells/microl (IQR 61-277) in South America, but 77%, 78% and 51%, respectively, started with <200 cells/microl in 2005-2006. In all regions baseline CD4 cell counts were higher in women than men: differences were 22cells/microl in Africa, 65 cells/microl in Asia and 10 cells/microl in South America. In 2005-2006 a viral load at 6 months was available in 21% of patients Africa, 8% of Asian patients and 73% of patients in South America. Corresponding figures for 6-month CD4 cell counts were 74%, 77% and 81%. CONCLUSIONS: The public health approach to providing ART proposed by the World Health Organization has been implemented in sub-Saharan Africa and Asia. Although CD4 cell counts at the start of ART have increased in recent years, most patients continue to start with counts well below the recommended threshold. Particular attention should be paid to more timely initiation of ART in HIV-infected men.
OBJECTIVES: To describe temporal trends in baseline clinical characteristics, initial treatment regimens and monitoring of patients starting antiretroviral therapy (ART) in resource-limited settings. METHODS: We analysed data from 17 ART programmes in 12 countries in sub-Saharan Africa, South America and Asia. Patients aged 16 years or older with documented date of start of highly active ART (HAART) were included. Data were analysed by calculating medians, interquartile ranges (IQR) and percentages by regions and time periods. Not all centres provided data for 2006 and 2005 and 2006 were therefore combined. RESULTS: A total of 36,715 patients who started ART 1996-2006 were included in the analysis. Patient numbers increased substantially in sub-Saharan Africa and Asia, and the number of initial regimens declined, to four and five, respectively, in 2005-2006. In South America 20 regimes were used in 2005-2006. A combination of 3TC/D4T/NVP was used for 56% of African patients and 42% of Asian patients; AZT/3TC/EFV was used in 33% of patients in South America. The median baseline CD4 count increased in recent years, to 122 cells/microl (IQR 53-194) in 2005-2006 in Africa, 134 cells/microl (IQR 72-191) in Asia, and 197 cells/microl (IQR 61-277) in South America, but 77%, 78% and 51%, respectively, started with <200 cells/microl in 2005-2006. In all regions baseline CD4 cell counts were higher in women than men: differences were 22cells/microl in Africa, 65 cells/microl in Asia and 10 cells/microl in South America. In 2005-2006 a viral load at 6 months was available in 21% of patients Africa, 8% of Asian patients and 73% of patients in South America. Corresponding figures for 6-month CD4 cell counts were 74%, 77% and 81%. CONCLUSIONS: The public health approach to providing ART proposed by the World Health Organization has been implemented in sub-Saharan Africa and Asia. Although CD4 cell counts at the start of ART have increased in recent years, most patients continue to start with counts well below the recommended threshold. Particular attention should be paid to more timely initiation of ART in HIV-infectedmen.
Authors: Charles F Gilks; Siobhan Crowley; René Ekpini; Sandy Gove; Jos Perriens; Yves Souteyrand; Don Sutherland; Marco Vitoria; Teguest Guerma; Kevin De Cock Journal: Lancet Date: 2006-08-05 Impact factor: 79.321
Authors: Suely H Tuboi; Martin W G Brinkhof; Matthias Egger; Roslyn A Stone; Paula Braitstein; Denis Nash; Eduardo Sprinz; François Dabis; Lee H Harrison; Mauro Schechter Journal: J Acquir Immune Defic Syndr Date: 2007-05-01 Impact factor: 3.731
Authors: Cheryl A Liechty; Peter Solberg; Willy Were; John Paul Ekwaru; Ray L Ransom; Paul J Weidle; Robert Downing; Alex Coutinho; Jonathan Mermin Journal: Trop Med Int Health Date: 2007-08 Impact factor: 2.622
Authors: Paula Braitstein; Andrew Boulle; Denis Nash; Martin W G Brinkhof; François Dabis; Christian Laurent; Mauro Schechter; Suely H Tuboi; Eduardo Sprinz; Paolo Miotti; Mina Hosseinipour; Margaret May; Matthias Egger; David R Bangsberg; Nicola Low Journal: J Womens Health (Larchmt) Date: 2008 Jan-Feb Impact factor: 2.681
Authors: A Spaar; C Graber; F Dabis; A Coutsoudis; L Bachmann; J McIntyre; M Schechter; H W Prozesky; S Tuboi; D Dickinson; N Kumarasamy; M Pujdades-Rodriquez; E Sprinz; H J Schilthuis; P Cahn; N Low; M Egger Journal: AIDS Care Date: 2010-06
Authors: Albert K Minga; Charlotte Lewden; Delphine Gabillard; Germain I Bomisso; Thomas-d'aquin Toni; Arlette A Emième; Vincent Yapo; André Inwoley; Roger Salamon; Xavier Anglaret Journal: AIDS Date: 2011-03-27 Impact factor: 4.177
Authors: Olivia Keiser; Hannock Tweya; Paula Braitstein; François Dabis; Patrick MacPhail; Andrew Boulle; Denis Nash; Robin Wood; Ruedi Lüthi; Martin W G Brinkhof; Mauro Schechter; Matthias Egger Journal: Trop Med Int Health Date: 2009-12-09 Impact factor: 2.622
Authors: Mathieu Forster; Christopher Bailey; Martin W G Brinkhof; Claire Graber; Andrew Boulle; Mark Spohr; Eric Balestre; Margaret May; Olivia Keiser; Andreas Jahn; Matthias Egger Journal: Bull World Health Organ Date: 2008-12 Impact factor: 9.408